tackling amr - new ways of working
TRANSCRIPT
Tackling AMR – new ways of workingGhada Zoubiane Programme Manager InfectionsMedical Research Council
MRC | Medical Research Council
• Established 1913• Funded by UK taxpayers• One of seven research councils
Dedicated to improving human health through the best scientific research.
MRC: Leading & Partnering Research
MRC | Medical Research Council
• Encourage and support high-quality research with the aim of improving human health
• Produce skilled researchers
• Advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK and worldwide
• Promote dialogue with the public about medical research
MRC Mission
Boards and Overview Groups
Molecular and Cellular
Medicine Board
Strategy Board
Population and Systems
Medicine Board
Infections and Immunity
Board
Neurosciences and Mental
Health Board
Public Health and Aging
Global Health
Capacity, Skills and Infrastructure
Clinical Research Support, Ethics and Methodology
Industry Liaison
Tran
slat
iona
l pr
ogra
mm
es Training program
mes
MRC Remit and Partners
• MRC: basic research to early clinical trials• Underpinning and aetiological• Prevention• Detection and diagnosis• Treatment development & evaluation• Phase 1 & 2 trials
• Other funders/partners• Department of Health / National
Institute of Health Research (NIHR)• Other Research Councils• Medical Charities• Industry• Innovate UK
Basic research Discovery Preclinical Early
Clinical Late
Clinical HTA
MRC
Medical CharitiesInnovate UK
NIHREME
BBSRC & EPSRC
MRC’s Translational Research Funding
Continued commitment to basic research
Basic research Prototype discovery & design
Pre-clinical development
Early clinical trials
Late clinical trials
Biomedical Catalyst: DPFS
MRC/NIHR Methodology Research Programme
BMC: RMRC
Translational Research Support
Health Technology Assessment
Efficacy, Mechanism
and EvaluationProgramme
MRC Lead NIHR Lead
Health Technology Assessment Programme
BMC: Confidence
in Concept
Innovate UK
Medical CharitiesBBSRC & EPSRC
• Confidence in Concept The aim is to accelerate the transition from discovery science to translational research i.e. to get projects to the point where they are well placed to seek funding for development (e.g. through BMC: DPFS) • Institutional awards of up to £1.2m over 24 months• Awards are intended to support multiple projects covering preliminary
work or feasibility studies; projects decided by university• Projects should be tightly defined, typically £50-100k in cost and
lasting 6-12months.• Proximity to Discovery
• Institutional awards of up to £250k • Promotion of academic-industry interactions• Supports ‘people exchange’ partnerships between academia and
industry, to enhance skills, knowledge and understanding.
Confidence in Concept and Proximity to Discovery
Biomedical Catalyst: Developmental Pathway Funding Scheme• ~£32m/year, rolling deadline every four months• Projects must be goal oriented and milestone-based• Projects are not considered as isolated entities – they must sit on a
translational pathway.In remit:• Development and pre-clinical testing of novel therapeutic entities,
devices and diagnostics through to early-phase clinical studies (P1 to P2a)
Out of remit:• Discovery science including mechanistic studies and biomarker
identification (MRC research boards)• Technology development where not aligned to a medical/clinical
developmental plan (likely BBSRC or EPSRC remit)• Phase 2b and 3 clinical trials & trials of non-novel agent-disease
combinations (NIHR).
AMR: A Complex Problem
Davies & Davies. Microbiol Mol Biol Rev. 2010 Sep; 74(3): 417–433.
UK spend on AMR (2007-2013)
£163m£56m
£16.8m
£16.6m
£0.49m £21.7mTherapeutics
Diagnostics
Surveillance
Transmission
Environment
Interventions
Total funding: £275mSpecifically on ABR
UnderpinningAlternativesOptimisationLead compounds
Kelly et.al, LID December 2015
What is needed?
• Collaborative working
• Coordination of key disciplinesMulti/inter/trans – disciplinary research
• Ensuring integration with human/animal healthcare
• Ensuring capacity building – supporting the next generation of AMR researchers
AMR Funders Forum (AMRFF)• Made up of representatives from the research councils,
governmental bodies and charities • Led and managed by the MRC• Strategically overview the UK AMR research base with an
understanding of its output, skill base, resources and impact• Has a common vision for AMR research and its implementation• Will add value to existing programmes• Will coordinate and/or support the initiation of funding and
delivery of programmes • Will raise the profile of the AMR research base in the UK and
internationallyhttp://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/antimicrobial-resistance-funders-forum/
AMR Cross-council Initiative
• Launched June 2014• All 7 Research Councils – led by MRC • Bacterial resistance in the first instance• 4 themes to tackle AMR
Funding models • Themed calls
• Kick start with £40m (phase 1)
• Networking / ‘Bridging the gap’/ AMR Champion
• Mixed funding models – ‘small high risk/high gain’ as well as larger multidisciplinary cross institutions
• Scalable approach
• Priority for the next 5-10 years
Steering Group
Herman Goossens (Chair) – University of Antwerp, Belgium Alastair Macdonald – Glasgow School of Art Duncan Maskell – University of Cambridge, UK Rachel McKendry – University College London, UK David Payne – GlaxoSmithKline Sharon Peacock – University of Cambridge/Bloomsbury
Institute, UK Richard Smith- London School of Hygiene and Tropical
Medicine, UK Jared Silverman – VL32 (ex-Cubist) Elizabeth Wellington – Warwick University, UK
Antimicrobial Resistance – a thematic approach
Understanding resistant bacteria
Accelerating therapeutic
and diagnostic development
Understanding real world
interactionsBehaviour within an beyond the
health care setting
Calls
clo
sed
2 Co
ll +
11 In
nov Calls
clo
sed
3 Co
ll +
8 In
nov
Calls
clo
sed
4 La
rge
+
9 pu
mp
prim
ing
Call
clos
ed
Revi
ew u
nder
way
Antimicrobial Resistance – Phase 1
• £40m commitment supporting multidisciplinary research from bench to bed side
• One Health approach, links with industry and policy makers, flexible funding model
• Ongoing call under “AMR and behaviour change” with DH and VMD/DEFRA
• Plans underway to engage with the Design community under ‘AMR in the built in environment’
• GCRF Challenge-led antibacterial resistance call: interdisciplinary & LMIC/DAC relevant collaborations/partnerships (autumn 2016) in collaboration with DH
• Target validation (currently being scoped)What is needed?What funding would show impact? Networks? Small projects? Collaborative? Links with industry at early stage?
Antimicrobial Resistance – Phase 2
• MRC represents the UK & are members of the Steering Group• To date, 19 members (17 EU countries, Canada & Israel), 3
observers (Argentina, Estonia and Japan) – expanding globally• Links with WHO, EC, IMI, EPFIA, TATFAR, NIH• Strategic Research Agenda highlights 6 priority topics – aligns to
UK AMR Cross Council Initiative• ‘One Health’ approach• Activities beyond calls that add value to national funding• Transnational calls and workshops
Joint Programming initiative on AMR
Developing International Links – Newton Fund
Partnership between UK and emerging knowledge countriesUK Funds matched from partner country - ODA
• UK-India Joint Centres Partnerships - 2 Centres on AMR The Cambridge-Chennai Centre Partnership on Antimicrobial Resistant
Tuberculosis UK-India Centre for Advanced Technology for Minimising the indiscriminate
use of Antibiotics (UKICAT-MA) • UK-China Call on AMR (MRC, ESRC, BBSRC)• UK-Thailand Joint Health Research call includes infectious diseases• UK-Vietnam Joint Infectious Disease Research call • UK-Brazil Neglected Infectious Diseases Partnership• UK-Philippines Joint Health Research call includes infectious diseases
(AMR)• UK-Indonesia Joint Health Research Call on Infectious diseases
More calls currently scoped for 2017
